Quarterly Period Covered: Six months ended June 28, 2026 (Q2 fiscal year 2026), filed July 23, 2026 Financial Reporting Structure: Contains consolidated financial statements including balance sheets, income statements, cash flow statements, and statements of equity for the six-month and quarter-to-date periods, with comparative prior year periods Debt Instruments Disclosed: Multiple series of…

Our analysis rates this filing NEUTRAL. Johnson & Johnson's Q2 2026 10-Q filing reflects standard pharmaceutical industry risk profiles without evidence of material deterioration or new existential threats. The three identified risks (litigation, derivatives, intangible assets) are typical for a…

Concern level: ELEVATED (5.2/10). Key factors: One high-severity risk identified: Litigation and Legal Contingencies (severity 7/10) with material financial exposure typical for pharmaceutical industry; Derivative instruments and hedging exposure (severity 6/10) creating potential mark-to-market volatility and counterparty credit risk; Intangible asset impairment risk (severity 6/10) from…

Notable risk changes: Extensive litigation and contingent liability tracking infrastructure indicates material legal exposure - typical for pharma but requires monitoring for reserve adequacy; Complex derivative hedging program (FX, interest rate swaps, cross-currency instruments) suggests significant treasury risk management needs and potential earnings volatility; Significant intangible assets (patents,…

The model predicts JNJ will underperform the S&P 500 by about 0.0% over 30 days (model confidence 50%). This is model analysis for research, not investment advice.